- Home
- O vs ZTS Comparison
O vs ZTS Comparison
Compare O & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | O | ZTS |
|---|---|---|
| Founded | 1969 | 1952 |
| Country | United States | United States |
| Employees | 544 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.5B | 48.7B |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | O | ZTS |
|---|---|---|
| Price | $62.34 | $117.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 11 |
| Target Price | $66.42 | ★ $156.20 |
| AVG Volume (30 Days) | ★ 5.4M | 3.2M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.21% | 1.80% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | N/A | ★ 6.02 |
| Revenue | N/A | ★ $9,467,000,000.00 |
| Revenue This Year | $6.08 | $5.67 |
| Revenue Next Year | $7.10 | $4.85 |
| P/E Ratio | $60.73 | ★ $19.54 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $50.71 | $113.30 |
| 52 Week High | $67.94 | $172.23 |
Technical Indicators
Market Signals| Indicator | O | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 46.55 | 46.47 |
| Support Level | $56.18 | $115.35 |
| Resistance Level | $65.82 | $130.52 |
| Average True Range (ATR) | 1.01 | 3.14 |
| MACD | -0.07 | 0.37 |
| Stochastic Oscillator | 41.70 | 49.78 |
Price Performance
Historical ComparisonAbout O Realty Income Corporation
Realty Income owns roughly 15,500 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, gaming, office, manufacturing, and distribution properties, which make up roughly 20% of revenue.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.